Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AKRO Akero Therapeutics	$56.19 -0.2%	$47.62	$21.02 ▼ $59.56	$4.48B	-0.16	1.04 million shs	3.83 million shs
AVDL Avadel Pharmaceuticals	$9.20 -1.0%	$9.16	$6.38 ▼ $17.30	$890.01M	1.45	1.22 million shs	2.69 million shs
MRUS Merus	$52.99 -0.4%	$48.89	$33.19 ▼ $62.98	$3.67B	1.04	743,249 shs	457,851 shs
OGN Organon & Co.	$9.87 -1.1%	$9.77	$8.01 ▼ $23.10	$2.57B	0.59	3.49 million shs	4.46 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AKRO Akero Therapeutics	0.00%	+3.67%	+10.13%	+38.81%	+139.51%
AVDL Avadel Pharmaceuticals	0.00%	+0.22%	+0.77%	+17.50%	-34.57%
MRUS Merus	0.00%	-0.21%	-4.85%	+25.90%	-10.44%
OGN Organon & Co.	0.00%	+1.07%	+7.27%	-33.86%	-52.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AKRO Akero Therapeutics	3.528 of 5 stars	3.5	1.0	0.0	4.7	1.9	0.8	0.0
AVDL Avadel Pharmaceuticals	2.4538 of 5 stars	3.5	3.0	0.0	0.0	1.5	1.7	0.6
MRUS Merus	1.9401 of 5 stars	3.6	1.0	0.0	0.0	2.0	2.5	0.0
OGN Organon & Co.	4.8394 of 5 stars	3.3	4.0	1.7	3.7	1.1	3.3	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AKRO Akero Therapeutics	3.00	Buy	$82.50	46.82% Upside
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	97.46% Upside
MRUS Merus	3.14	Buy	$84.64	59.72% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	82.39% Upside

Current Analyst Ratings Breakdown

Latest AVDL, AKRO, OGN, and MRUS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	AKRO Akero Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$63.00 ➝ $64.00
5/23/2025	MRUS Merus	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$96.00 ➝ $110.00
5/22/2025	OGN Organon & Co.	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/19/2025	MRUS Merus	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
5/15/2025	OGN Organon & Co.	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$24.00 ➝ $18.00
5/13/2025	AKRO Akero Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $78.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
5/8/2025	MRUS Merus	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$91.00 ➝ $89.00
5/5/2025	OGN Organon & Co.	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $10.00
5/2/2025	OGN Organon & Co.	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Inline
4/28/2025	MRUS Merus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	$10.75 per share	N/A
AVDL Avadel Pharmaceuticals	$169.12M	5.26	N/A	N/A	$0.77 per share	11.95
MRUS Merus	$54.73M	67.01	N/A	N/A	$9.46 per share	5.60
OGN Organon & Co.	$6.40B	0.40	$4.93 per share	2.00	$1.83 per share	5.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AKRO Akero Therapeutics	-$252.06M	-$1.95	N/A	N/A	N/A	N/A	-15.19%	-13.97%	8/8/2025 (Estimated)
AVDL Avadel Pharmaceuticals	-$48.83M	-$0.27	N/A	153.33	N/A	-13.58%	-36.07%	-16.30%	8/6/2025 (Estimated)
MRUS Merus	-$215.33M	-$4.08	N/A	N/A	N/A	-506.73%	-35.99%	-29.83%	7/30/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.43	2.64	1.03	11.92%	227.43%	7.34%	8/5/2025 (Estimated)

Latest AVDL, AKRO, OGN, and MRUS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MRUS Merus	-$1.17	-$1.40	-$0.23	-$1.40	$7.82 million	$26.49 million
5/12/2025	Q1 2025	AKRO Akero Therapeutics	-$1.01	$0.90	+$1.91	$0.90	N/A	N/A
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/1/2025	Q1 2025	OGN Organon & Co.	$0.89	$1.02	+$0.13	$0.33	$1.53 billion	$1.51 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AKRO Akero Therapeutics	N/A	N/A	N/A	N/A	N/A
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRUS Merus	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.81%	N/A	2.78%	N/A

Latest AVDL, AKRO, OGN, and MRUS Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
5/2/2025	OGN Organon & Co.	quarterly	$0.02	0.8%	5/12/2025	5/12/2025	6/12/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AKRO Akero Therapeutics	0.03	16.80	16.80
AVDL Avadel Pharmaceuticals	N/A	2.73	2.33
MRUS Merus	N/A	5.86	5.86
OGN Organon & Co.	16.49	1.67	1.15

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AKRO Akero Therapeutics	N/A
AVDL Avadel Pharmaceuticals	69.19%
MRUS Merus	96.14%
OGN Organon & Co.	77.43%

Insider Ownership

Company	Insider Ownership
AKRO Akero Therapeutics	7.07%
AVDL Avadel Pharmaceuticals	5.20%
MRUS Merus	4.57%
OGN Organon & Co.	1.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AKRO Akero Therapeutics	30	79.72 million	74.08 million	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.71 million	Optionable
MRUS Merus	37	69.21 million	66.05 million	Optionable
OGN Organon & Co.	4,000	259.96 million	256.32 million	Not Optionable

AVDL, AKRO, OGN, and MRUS Headlines

Recent News About These Companies

Organon & Co. (NYSE:OGN) Shares Acquired by Illinois Municipal Retirement Fund

2 hours ago | marketbeat.com

ROSEN, SKILLED INVESTOR COUNSEL, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action - OGN

June 29 at 1:34 PM | markets.businessinsider.com

INVESTOR DEADLINE: Robbins Geller Announces that Organon & Co. ...

June 28 at 7:42 PM | gurufocus.com

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of ...

June 28 at 7:42 PM | gurufocus.com

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud ...

June 28 at 7:42 PM | gurufocus.com

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Organon & Co. ...

June 28 at 7:41 PM | gurufocus.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co.of Class Action Lawsuit and Upcoming Deadlines - OGN

June 28 at 10:00 AM | globenewswire.com

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Organon & Co. Investors to Secure Counsel Before Important Deadline in Securities Class Action – OGN

June 28 at 9:42 AM | globenewswire.com

OGN Investors Have the Opportunity to Lead the Organon Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

June 28 at 8:20 AM | globenewswire.com

OGN INVESTOR DEADLINE: Organon & Co. Investors with Losses may have been Affected by Fraud – Contact BFA Law by July 22 Court Deadline (NYSE:OGN)

June 28 at 7:46 AM | globenewswire.com

OGN - Organon & Co Ordinary Shares Dividends - Morningstar

June 27 at 12:09 AM | morningstar.comM

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

June 27 at 10:38 PM | prnewswire.com

INVESTOR DEADLINE: Robbins Geller Announces that Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

June 27 at 9:30 PM | globenewswire.com

Lost Money on Organon & Co.(OGN)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky

June 27 at 4:08 PM | globenewswire.com

OGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Organon & Co. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

June 27 at 4:00 PM | globenewswire.com

Deadline Alert: Organon & Co. (OGN) Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

June 27 at 12:00 PM | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Organon & Co. of Class Action Lawsuit and Upcoming Deadlines - OGN

June 27 at 10:00 AM | prnewswire.com

OGN Lawsuit Alert! Class Action Lawsuit Against Organon & Co.

June 27 at 9:26 AM | tipranks.com

OGN LAWSUIT ALERT: Levi & Korsinsky Notifies Organon & Co. Investors of a Class Action Lawsuit and Upcoming Deadline

June 27 at 9:00 AM | prnewswire.com

OGN Investors Have the Opportunity to Lead the Organon Securities Fraud Lawsuit with Faruqi & Faruqi, LLP

June 26, 2025 | prnewswire.com

OGN Investors Have Opportunity to Lead Organon & Co. Securities Fraud Lawsuit

June 26, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
Intel's Turnaround Strategy Shifts From Planning to Attack Mode
By Jeffrey Neal Johnson | June 20, 2025
View Intel's Turnaround Strategy Shifts From Planning to Attack Mode
3 Semiconductor Stocks Poised to Surge on AI Spending
By Chris Markoch | June 25, 2025
View 3 Semiconductor Stocks Poised to Surge on AI Spending
Investors Are Waking Up to Arista Networks—Here’s the Scoop
By Jeffrey Neal Johnson | June 26, 2025
View Investors Are Waking Up to Arista Networks—Here’s the Scoop

AVDL, AKRO, OGN, and MRUS Company Descriptions

Akero Therapeutics NASDAQ:AKRO

$56.19 -0.09 (-0.16%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$59.56 +3.37 (+6.00%)

As of 05:29 AM Eastern

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Avadel Pharmaceuticals NASDAQ:AVDL

$9.20 -0.09 (-0.97%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$16.00 +6.80 (+73.91%)

As of 04:00 AM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Merus NASDAQ:MRUS

$52.99 -0.19 (-0.36%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$52.94 -0.05 (-0.08%)

As of 04:00 AM Eastern

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; collaboration with Incyte Corporation for the development of MCLA-145; and collaboration with Gilead Sciences, Inc. to discover novel antibody-based trispecific T-cell engagers. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.

Organon & Co. NYSE:OGN

$9.87 -0.11 (-1.11%)

Closing price 06/27/2025 03:59 PM Eastern

Extended Trading

$9.94 +0.07 (+0.72%)

As of 05:07 AM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time